Mechanistic insights into conformational changes that accompany the binding of negative allosteric modulators to the cannabinoid receptor 1 by Aderibigbe, AyoOluwa et al.
AyoOluwa O. Aderibigbe1, Pankaj Pandey2, and Robert J. Doerksen*1,3
1Department of BioMolecular Sciences, Division of Medicinal Chemistry, 1,2National Center for Natural Products Research, and 3Research Institute of Pharmaceutical Sciences
School of Pharmacy, University of Mississippi, University, MS 38677, USA 
Mechanistic insights into conformational changes that 
accompany the binding of negative allosteric modulators
to the cannabinoid receptor 1
Background
§ The human cannabinoid receptor 1 (CB1) is considered a promising
therapeutic target for the management of obesity.
§ Conventional antagonists of the CB1 receptor—small molecules (ligands) that
bind at the orthosteric site (putative site for the receptor’s endogenous
ligands)—inhibit receptor signaling and have been shown to induce body
weight reduction.
§ Many of these ligands are active in the CNS, in which they induce adverse
neuropsychiatric effects.
§ Rimonabant, a CB1 antagonist that showed promising results in the
management of obesity, was withdrawn from the European market
following reports of suicidal ideations in certain patients1.
§ To avoid these adverse neuropsychiatric effects, various strategic design
targets have been proposed:
§ CB1 negative allosteric modulators (NAMs)2
§ CB1 NAMs are ligands that bind at a site topologically distinct from the
orthosteric site and inhibit CB1 receptor signaling
§ CB1 orthosteric antagonists that are peripherally-restricted3
§ CB1 neutral orthosteric antagonists, which would not reduce CB1 signaling
levels below the basal level4
§ Recently, an X-ray crystal structure of CB1 (PDB ID: 6KQI) bound to
ORG27569, a CB1 NAM, and CP55940, a well-known cannabinoid agonist,
was released5 (Fig. 1).
§ Proposed workflow for the study is shown in Fig. 2.
§ MD simulations. Two independent runs of 100 ns MD
simulations will be performed on each of the seven
CB1 complexes (Table 1).
§ Snapshots will be saved at an interval of 10 ps using
the Desmond MD simulation program11 (n = 140,000).
§ Selection of conformational features. Two types of
descriptors will be calculated for amino acid residues
of CB1.
§ The C⍺–C⍺ distances of all pairs of residues (as
can be obtained from a distance matrix (Fig. 3).
§ The χ1 and χ2 torsion angles of the CB1 residues.
Ø Descriptors will be determined only for residues
located within a helical secondary structure and
residues fully resolved in all seven experimental
structures.
§ The dimensionality of the data will be reduced using
a neural network implemented using TensorFlow12.
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Fig. 1. Left: 2D structures of the CB1 agonist, CP55940, and NAMs, ORG27569 and 
PSNCBAM-1. Right: CB1 receptor with CP55940 (C purple) and ORG27569 (C cyan), 
with microswitch residues shown using stick model (C grey) (from PDB: 6KQI). 
Ø Hence, our aim is to identify a set of CB1 receptor attributes that distinguish the NAM-bound intermediate state
from the active and inactive states of CB1.
§ This study will
§ Provide insights into intramolecular signaling transduction and biased signaling that accompanies NAM binding to
CB1.
§ Improve prediction accuracies of computational studies on the binding modes of CB1 allosteric ligands, for which
experimental structures of the complexes are not available yet.




Fig. 3. C⍺–C⍺ distance matrix of the intermediate-state CB1 
structure (PDB ID: 6KQI). 
§ Conformations of a receptor provide insight into its functional state, as certain
conformational features have distinctive values in different receptor functional
states.
§ Currently, there are seven experimental 3D structures of the human CB1
receptor available, belonging to three functional states:
§ Intermediate state (PDB ID: 6KQI)5.
§ Active state (PDB IDs: 5XRA, 5XR8, 6N4B, and 6KPG)6-8.
§ Inactive state (PDB IDs: 5TGZ and 5U09)9,10.
§ Certain microswitches (receptor conformational features that are distinctive
between different functional states) have been identified for the active and
inactive states of CB1 such as the ionic lock between R214 and D338 and the
rotameric toggle switch residues, F200 and W356 (Fig. 1).
§ However, there are no receptor attributes (or set of attributes) that have
been identified to differentiate the intermediate state from the other two
functional states.
Expected Outcomes
§ A set of conformational features that
can be used to distinguish the NAM-
bound intermediate conformation of
CB1 from its active- and inactive-state
structures.
§ Assessment of the identified features
from snapshots following MD
simulation of the CB1–CP55940–
PSNCBAM-1 complex will show that
values of the features fall within the
same range as those identified for the
ORG27569-bound ternary complex.
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Table 1. MD simulation systems.
Fig. 2. Proposed workflow for the project.
§ Random forest modeling. 75% of the dataset (n) will be
used to train models, while the remaining 25% will be
used to test models.
§ Training of decision trees will be repeated 100 times.
§ Prediction of important descriptors will be based on
the average contribution of the 100 models.
§ Assessment of identified features with a predicted
intermediate-state conformation of PSNCBAM-1 in
complex with CP55940-bound CB1.
§ PSNCBAM-1 will be docked into the allosteric binding
pocket identified in 6KQI.
§ A complex obtained from the best docking solution will
be submitted for a 200 ns MD simulation.
§ Identified functional state-distinguishing features will
be assessed from snapshots taken at 10 ps intervals
from the last 10 ns of the simulation.
§ Known CB1 microswitches of the
intermediate-state CB1 structure,
6KQI, match the inactive-state
conformation.
§ However, the co-bound CB1 agonist
indicates that an active-state
conformation is adopted surrounding
the orthosteric site.
§ MD simulations of the 5XRA, 5U09
and 6KQI have been completed and
are ready to be analyzed.
Preliminary data
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